Prevalence of rifampicin-resistant Mycobacterium tuberculosis among human-immunodeficiency-virus-seropositive patients and their treatment outcomes

C.K. Vidyaraj; A. Chitra; S. Smita; M. Muthuraj; S. Govindarajan; B. Usharani; S. Anbazhagi

doi:10.1016/j.jegh.2017.09.002

<Previous Article In Issue

Next Article In Issue>

Volume 7, Issue 4, December 2017, Pages 289 - 294

Prevalence of rifampicin-resistant Mycobacterium tuberculosis among human-immunodeficiency-virus-seropositive patients and their treatment outcomes

Authors

C.K. Vidyaraj^a, A. Chitra^a, S. Smita^a, M. Muthuraj^a^{, *}^,muthuraj1970@gmail.com, S. Govindarajan^a, B. Usharani^b, S. Anbazhagi^c

^aState TB Training and Demonstration Centre, Intermediate Reference Laboratory, Government Hospital for Chest Diseases, Puducherry, India

^bDepartment of Genetics, Madras University, Tamil Nadu, India

^cDepartment of Environment Sciences, Central University, Kerala, India

^*Corresponding author.

Corresponding Author

M. Muthurajmuthuraj1970@gmail.com

Received 7 June 2017, Revised 26 August 2017, Accepted 13 September 2017, Available Online 21 September 2017.

DOI: 10.1016/j.jegh.2017.09.002 How to use a DOI?
Abstract: Multidrug resistant (MDR) and extensively drug resistant tuberculosis (TB) are a threat to the TB control programs in developing countries, and the situation is worsened by the human immunodeficiency virus (HIV) pandemic. This study was performed to correlate treatment outcome with the resistance patterns in HIV-seropositive patients coinfected with pulmonary TB. Sputum specimens were collected from 1643 HIV-seropositive patients and subjected to microscopy and liquid culture for TB. The smear- and culture-positive Mycobacterium tuberculosis isolates were subjected to Genotype MTBDRplus assay version 2.0. The M. tuberculosis culture-positivity rate was 39.44% (648/1643) among the 1643 HIV-seropositive patients and the overall MDR-TB rate was 5.6% (36/648). There were 421 newly diagnosed and 227 previously treated patients, among whom, MDR-TB was associated with 2.9% and 10.57% cases, respectively. The rate of rifampicin monoresistant TB among the cases of MDR-TB was 2.31% (15/648) and the rate of combined rifampicin and isoniazid resistance was 3.24% (21/648). The cure and death rates among the 20 registered cases were 30% (6/20) and 35% (7/20), respectively. Five cases were on treatment and two cases were defaulters among the 20 registered cases. High death rate (13, 36.1%, 95% confidence interval 20.8–53.8) was observed in this study among the patients who had mutations at the 530–533 codons. The present study emphasized the prerequisite to monitor the trend of drug-resistant TB in various mutant populations in order to timely implement appropriate interventions to curb the threat of MDR-TB.
Open Access: This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Download article (PDF)
View full text (HTML)

<Previous Article In Issue

Next Article In Issue>

Journal: Journal of Epidemiology and Global Health
Volume-Issue: 7 - 4
Pages: 289 - 294
Publication Date: 2017/09/21
ISSN (Online): 2210-6014
ISSN (Print): 2210-6006
DOI: 10.1016/j.jegh.2017.09.002 How to use a DOI?
Open Access: This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Cite this article

ris enw bib

TY  - JOUR
AU  - C.K. Vidyaraj
AU  - A. Chitra
AU  - S. Smita
AU  - M. Muthuraj
AU  - S. Govindarajan
AU  - B. Usharani
AU  - S. Anbazhagi
PY  - 2017
DA  - 2017/09/21
TI  - Prevalence of rifampicin-resistant Mycobacterium tuberculosis among human-immunodeficiency-virus-seropositive patients and their treatment outcomes
JO  - Journal of Epidemiology and Global Health
SP  - 289
EP  - 294
VL  - 7
IS  - 4
SN  - 2210-6014
UR  - https://doi.org/10.1016/j.jegh.2017.09.002
DO  - 10.1016/j.jegh.2017.09.002
ID  - Vidyaraj2017
ER  -

download .riscopy to clipboard